TVTX

Travere Therapeutics, Inc. (TVTX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Travere Therapeutics is a biopharmaceutical company focused on rare kidney and metabolic diseases. The company's primary commercial product is FILSPARI (sparsentan), approved for primary Immunoglobulin A nephropathy (IgAN). The company is also advancing clinical programs for sparsentan in Focal Segmental Glomerulosclerosis (FSGS) and pegtibatinase for classical homocystinuria (HCU).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 111% year-over-year for the quarter and 105% year-over-year for the six months. This was driven by a 165% increase in FILSPARI sales and a significant regulatory milestone payment.
• Milestone Payment: License and collaboration revenue surged due to a $17.5 million regulatory milestone received in May 2025 from CSL Vifor following the conversion of FILSPARI's conditional marketing authorization to a standard marketing authorization in the European Union.
• Improved Profitability: Net loss narrowed significantly to $12.8 million for the quarter compared to $70.4 million in the prior year period, primarily due to revenue growth and a reduction in operating expenses.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by $11.4 million (Q2) and $20.1 million (YTD) due to higher intangible asset amortization from capitalized royalties and increased commercial investment for FILSPARI. Research and development (R&D) expenses decreased by $5.0 million (Q2) and $7.5 million (YTD), largely due to the pause in the pegtibatinase HARMONY Study.

Guidance, Outlook, and Risks

• FSGS Approval Pathway: In March 2025, the company submitted a supplemental New Drug Application (sNDA) for FILSPARI for the treatment of FSGS. The FDA accepted the sNDA in May 2025, assigned a PDUFA target action date of January 13, 2026, and plans to hold an advisory committee meeting.
• Pegtibatinase Development: Enrollment in the Phase 3 HARMONY Study for pegtibatinase remains paused as the company addresses manufacturing scale-up process improvements. The company anticipates restarting enrollment in 2026.
• Debt Maturity: The company has $68.9 million in 2.5% Convertible Senior Notes due September 15, 2025, which are classified as current liabilities. Management believes current cash and short-term investments are sufficient to fund operations beyond the next 12 months.
• Regulatory & Tax Updates: The "One Big Beautiful Bill Act" (OBBBA) was signed into law on July 4, 2025, enacting significant tax changes. The company does not anticipate a material change to its effective tax rate due to its full valuation allowance. Additionally, the FDA is reviewing a request to modify the REMS for liver monitoring for FILSPARI, with a PDUFA date of August 28, 2025.

Investor Verification Checklist

• Debt Refinancing: Verify the company's plan to refinance or repay the $68.9 million in convertible notes maturing in September 2025.
• FSGS Advisory Committee: Monitor the timing and outcome of the FDA advisory committee meeting regarding the FSGS sNDA, as this is critical for future revenue potential.
• Pegtibatinase Restart: Confirm the timeline for resuming the Phase 3 HARMONY Study and the resolution of manufacturing scale-up issues.
• Commercial Execution: Assess the growth trajectory of FILSPARI sales in the U.S. and Europe, particularly following the standard EU marketing authorization.
• Generic Competition: Review the impact of generic competition on Thiola and Thiola EC sales, which have faced erosion from generic entrants.